# Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers

> **NCT03495609** · PHASE4 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 33 (actual)

## Conditions studied

- hCG
- BRCA1 Mutation
- BRCA2 Mutation

## Interventions

- **DRUG:** Ovitrelle

## Key facts

- **NCT ID:** NCT03495609
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-17
- **Primary completion:** 2018-12-18
- **Final completion:** 2018-12-18
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2023-09-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03495609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03495609, "Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03495609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*